WindRose Recapitalizes Verified Clinical Trials
Tuesday, August 18, 2026 · first reported by Private Equity Professional
WindRose Health Investors recapitalizes Verified Clinical Trials, a global clinical research subject registry; Howard Miller appointed new CEO. Cantor Fitzgerald & Co. and law firms advised.
- Also named
- Verified Clinical Trials, Cantor Fitzgerald & Co.
- People
- Howard Miller
- Asset class
- Private equity
- Geography
- North America
Advisers McDermott Will & Schulte (legal counsel), Latham & Watkins (legal counsel)
In the directory
- Latham & Watkins · Legal counsel · fund lawyers at the firm
- McDermott Will & Schulte · Legal counsel · fund lawyers at the firm
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore in Deals
From the same day- Goldman Sachs to Buy Real-Estate Investment Firm for Up to $410 MillionWSJ +1
- Brookfield targets Reliance Worldwide in $2.9bn dealPrivate Equity Wire +1
- Steadfast Extends Amwins–Dragoneer–KKR Exclusivity to August 21 at A$6.00HedgeCo
- Francisco Partners to take health tech firm Weave private for $650mPE Hub +1
- Rockbridge agrees to sell healthcare media firm CheckedUp to Providence EquityPE Hub
- Agellus-backed Bluejack snaps up Phillips Fire & Life SafetyPE Hub